NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ALORA (estradiol) by AbbVie is characteristics. Approved for menopause, postmenopausal vaginal atrophy, turner syndrome and 5 more indications. First approved in 1996.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALORA is a transdermal estradiol film approved in 1996 that delivers the primary human estrogen through the skin for 3-4 days per application. It treats menopausal symptoms, vaginal atrophy, hypogonadism, and Turner syndrome by binding to nuclear estrogen receptors to restore hormone levels and reduce elevated gonadotropins. Estradiol is substantially more potent than its metabolites estrone and estriol at the receptor level.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), opportunities are concentrated in brand defense and generics preparation rather than growth initiatives.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (8)
Worked on ALORA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.